ChemicalBook > CAS DataBase List > WNK inhibitor 12

WNK inhibitor 12

Product Name
WNK inhibitor 12
CAS No.
2123483-49-6
Chemical Name
WNK inhibitor 12
Synonyms
WNK-476;WNK 476;WNKIN12;WNK IN 12;WNK-IN-12;WNK-IN-11-d3;WNK inhibitor 12;WNK IN 11 d3,WNK-IN-11-d-3,WNKIN11d3
CBNumber
CB94668672
Molecular Formula
C21H21Cl2N5OS
Formula Weight
462.39
MOL File
2123483-49-6.mol
More
Less

WNK inhibitor 12 Property

storage temp. 
Store at -20°C
form 
Solid
color 
Off-white to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

WNK inhibitor 12 Chemical Properties,Usage,Production

Uses

WNK-IN-11-d3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d3 is effective at regulating cardiovascular homeostasis[1].

Biological Activity

WNK-IN-11 D3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11 D3 is effective at regulating cardiovascular homeostasis[1]. WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability[1].WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice[1].WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg[1].WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload[1].

in vivo

WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability[1].
WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice[1].
WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg[1].
WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload[1].

Animal Model:Sprague?Dawley rats[1]
Dosage:1.5 mg/kg
Administration:P.o.
Result:Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
Animal Model:FVB mice[1]
Dosage:30 mg/kg
Administration:P.o.
Result:Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.
Animal Model:FVB mice[1]
Dosage:0~100 mg/kg
Administration:P.o.
Result:Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.

References

[1]. Yamada K, Levell J, Yoon T, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017;60(16):7099-7107.

WNK inhibitor 12 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

WNK inhibitor 12 Suppliers

TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
Guangzhou Baide Biotechnology Co., Ltd.
Tel
18925065404
Country
CHINA
ProdList
168
Advantage
58

2123483-49-6, WNK inhibitor 12Related Search:


  • WNK inhibitor 12
  • WNK 476
  • WNK-476
  • WNK IN 12
  • WNKIN12
  • WNK-IN-12
  • WNK-IN-11-d3
  • WNK IN 11 d3,WNK-IN-11-d-3,WNKIN11d3
  • 2123483-49-6